Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3398455 | Clinical Microbiology and Infection | 2008 | 4 Pages |
Abstract
ABSTRACTThis study investigated the long-term outcome of patients with tuberculosis (TB) as a complication of tumour necrosis factor (TNF)-α blocker therapy. All TB cases (n = 21) complicating TNF-α blocker therapy from French university hospitals were collated between January 2000 and September 2002. Outcome was assessed via a postal questionnaire during September 2005. The mortality rate after 4 years was 4.8%, and one patient had relapsed and six (29%) patients had recommenced TNF-α antagonist treatment, after appropriate anti-TB therapy, without reactivation. These data support the concept that TNF-α antagonists can be restarted in TB patients provided that adequate anti-TB treatment has been completed.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
B. Denis, A. Lefort, R.M. Flipo, F. Tubach, M. Lemann, P. Ravaud, D. Salmon, X. Mariette, O. Lortholary,